AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study says Cypher stent superior to bare-metal stents
A Medical Device Daily Staff Report
Cordis (Miami Lakes, Florida) reported that the Cypher sirolimus-eluting coronary stent reduced the risk of target-vessel failure (TVF) by almost half in patients who suffered acute myocardial infarction (AMI), compared to those treated with balloon angioplasty and a bare-metal stent (BMS), according to data appearing recently in the New England Journal of Medicine.
At one year post-implantation, the study found that patients given the Cypher stent were 49% less likely to experience TVF than those given a BMS. Patients in the Cypher stent arm had a TVF rate of 7.3% compared to 14.3% in the BMS arm of the study (p
The data were originally presented at the American College of Cardiology annual scientific session in March. TYPHOON (the trial to assess the use of the Cypher Stent in AMI treated with balloon angioplasty), sponsored by Cordis, is the first to study the safety and efficacy of the Cypher stent in patients who have suffered an AMI, the company said. Data were reported on 712 patients who had suffered an AMI within 12 hours before the stent placement. TYPHOON was conducted at 48 sites across Europe, Israel and Australia.